Nationwide Children's spinoff gets FDA OK to test persistent pneumonia treatment in humans
October 06, 2022 at 12:43 PM EDT
Clarametyx Biosciences Inc. announced Wednesday that the U.S. Food and Drug Administration accepted the Columbus company’s application to test the safety of its treatment for antibiotic-resistant infections, in both healthy volunteers and patients hospitalized with pneumonia.
